From mice to man: The preclinical history of mycophenolate mofetil

Clinical Transplantation

Volumn 10, Issue 1 II, 1996, Pages 85-92

  Sollinger, Hans W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Allograft rejection; Immunosuppression; Mycophenolate mofetil; Mycophenolic acid; Preclinical

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; PRODRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HEMORRHAGIC GASTRITIS; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE FUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MICE; MYCOPHENOLIC ACID; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029865963     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. ALLISON AC, EUGUI EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996: 10: 77.
2. ALLISON AC, EUGUI EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993: 14: 353.
3. ALLISON AC, EUGUI EM. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 1993: 25 (suppl 2): 8.
4. ALLISON AC, EUGUI EM. Mycophenolate mofetil (RS-61443): mode of action and effects on graft rejection. In: THOMPSON AW, STARZL TF, eds. Immunosuppressive Drugs, Developments in Anti-Rejection Therapy. New York: Edward Arnold, 1994: 141.
5. EUGUI EM, ALLISON AC. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 1993: 685: 309.
6. MORRIS RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993: 12: S275.
7. YOUNG CJ, SOLLINGER HW. RS-61443: a new immunosuppressive agent. Transplant Proc 1994: 26: 3144.
8. EUGUI EM, MIRKOVICH A, ALLISON AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid in mice. Scand J Immunol 1991: 33: 175.
9. LEE WA, GU L, MIKSZTAL AR, CHU N, LEUNG K, NELSON PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7: 161.
10. EUGUI EM, MIRKOVICH A, ALLISON AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 1991: 23 (suppl 2): 15.
11. FIGUEROA J, FUAD SA, KUNJUMMEN BD, PLATT JL, BACH FH. Suppression of synthesis of natural antibodies by mycophenolate mofetil (RS-61443). Transplantation 1993: 55. 1371.
12. MORRIS RE, HOYT EG, EUGUI EM, ALLISON AC. Prolongation of rat heart allograft survival by RS 61443. Surg Forum 1989: 40: 337.
13. MORRIS RE, HOYT EG, MURPIIY MP, EUGUI EM, ALLISON AC. Mycophenolic acid morpholinoethylester (RS-16443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990: 22: 1659.
14. MORRIS RE, WANG J, BLUM JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients in heart allografts. Transplant Proc 1991: 23 (suppl 2): 19.
15. KNECHTLE SJ, WANG J, BURLINGHAM WJ, BEESKAU M, SUBRAMANIAN R, SOLLINGER HW. The influence of RS-61443 on antibody-mediated rejection. Transplantation 1992: 699.
16. KAWAMURA T, HULLETT DA, SUZUKI Y, BECHSTEIN WO, ALLISON AM, SOLLINGER HW. Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy. Transplantation 1993: 55: 691.
17. STEELE DM, HULLETT DA, BECHSTEIN WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993: 25: 754.
18. RÄISÄNEN-SOKOLOWSKI A, MYLLÄRNIEMI M, HÄYRY P. Effect of mycophenolate mofetil on allograft arteriosclerosis (chronic rejection). Transplant Proc 1994: 26: 3225.
19. HAO L, LAFFERTY KJ, ALLISON AC, EUGUI EM. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990: 22: 876.
20. HAO L, CALCINARO F, GILL RG, EUGUI EM, ALLISON AC, LAFFERTY KJ. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 1992: 53: 590.
21. HAO L, WANG Y, CHAN S-M, LAFFERTY KJ. Effect of mycophenolate mofetil on islet allografting to chemically induced or spontaneously diabetic animals. Transplant Proc 1992: 24: 2843.
22. PLATZ KP, SOLLINGER HW, HULLETT DA, ECKHOFF DE, EUGUI EM, ALLISON AC. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991: 51: 27.
23. PLATZ KP, BECHSTEIN WO, ECKHOFF DE, SUZUKI Y, SOLLINGER HW. RS-61443 reverses acute allograft rejection in dogs. Surgery 1991: 110: 736.
24. PLATZ KP, ECKHOFF DE, HULLETT DA, SOLLINGER HW. RS-61443 studies. review and proposal. Transplant Proc 1991: 23 (suppl 2): 33.
25. D'ALESSANDRO AM, RANKIN M, MCVEY J, et al. Prolongation of caaine intestinal allograft survival with RS-61443, cyclosporine, and prednisone. Transplantation 1993: 55: 695.
26. NAKAJIMA K, OCHIAI T, NAGATA M, et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. Transplant Proc 1993: 25: 595.
27. D'ALESSANDRO AM, RANKIN MA. Heterotopic rat intestinal transplantation: effect of cyclosporine and RS-61443 on graft-vs-host disease and rejection. Transplant Proc 1994: 26: 1611.
28. SHAFFER D, BLAKELY ML, GOTTSCHALK R, MONACO AP. Small bowel transplantation in rats using RS-61443: effect on GVHD and rejection. Transplant Proc 1992: 24: 1159.
29. BECHSTEIN WO, SCHILLING M, STEELE DM, HULLETT DA, SOLLINGER HW. RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993: 25: 702.
30. BENHAIM P, ANTHONY JP, LIN LY-T, MCCALMONT TH, MATHES SJ. A long-term study of allogeneic rat hindlimb transplants immunosuppressed with RS-61443. Transplantation 1993: 56: 911.
31. VAN DEN HELDER TBM, BENHAIM P, ANTHONY JP, MCCALMONT TH, MATHES SJ. Efficacy of RS-61443 in reversing acute rejection in a rat model of hindlimb allotransplantation. Transplantation 1994: 57: 427.
32. HULLETT DA, LANDRY AS, ECKHOFF DE, et al. DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs mouse murine thyroid allograft survival. Transplant Proc 1993: 25: 756.
33. HULLETT DA, KAWAMURA T, FUJINO Y, ALLISON AM, SOLLINGER HW. Prolongation of allograft and xenograft survival with mycophenolate mofetil (RS-61443) and brequinar sodium (DUP-785). Transplant Proc 1993: 25: 700.
34. FUJINO Y, KAWAMURA T, HULLETT DA, SOLLINGER HW. Evaluation of cyclosporine. mycophenolate mofetil, and brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation. Transplantation 1994: 57: 41.
35. MCMANUS RP, O'HAIR DP, KOMOROWSKI R, SCOTT JP. Immunosuppressant combinations in primate cardiac xenografts. Ann N Y Acad Sci 1993: 696: 281.
36. O'HAIR DP, MCMANUS RP, KOMOROWSKI R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994: 58: 1311.
37. BEGER C, VAJKOCZY P, MENGER MD, MESSMER K. Effects of RS-61443 on pancreatic islet xenografts. Transplant Proc 1994: 26: 759.
38. SOLLINGER HW, DEIERHOI MH, BELZER FO, DIETHELM AG, KAUFFMAN RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992: 53: 428.
39. DEIERHOI MH, SOLLINGER HW, DIETHELM AG, BELZER FO, KAUFFMAN RS. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant Proc 1993: 25: 693.
40. DEIERHOI MH, KAUFFMAN RS, HUDSON SL, et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993: 217: 476.
41. SALAMAN JR, GRIFFIN PJA, JOHNSON RWG, et al. Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy. Transplant Proc 1993: 25: 695.
42. SOLLINGER HW, BELZER FO, DEIERHOI MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992: 216: 513.
43. LASKOW DA, DEIERHOI MH, HUDSON SL, ORR CL, CURTIS JJ, DIETHELM AG. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443). Transplantation 1994: 57: 640.
44. KUNTMALM GB, ASCHER NL, BUSUTTIL RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993: 25: 697.
45. PREISE CE, HEBERT M, OSORIO RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993: 25: 1758.
46. ENSLEY RD, BRISTOW MR, OLSEN SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993: 56: 75.